05:13 AM EDT, 06/14/2024 (MT Newswires) -- Vertex Pharmaceuticals ( VRTX ) said Friday its Casgevy gene-editing therapy demonstrated clinical benefits in trials in sickle cell disease and transfusion-dependent beta thalassemia. In sickle cell disease, about 92% of evaluable patients were shown to be free from vaso-occlusive crises, or VOCs, for at least 12 months, while 97% of patients with...

05:10 AM EDT, 06/14/2024 (MT Newswires) -- Editas Medicine ( EDIT ) said Friday that new data in a phase 1/2 trial of its gene-editing cell therapy medicine renizgamglogene autogedtemcel showed its was well-tolerated and had a safety profile consistent with other treatments of patients with sickle-cell disease, a blood disorder. The company describes the drug, also called reni-cel, as...

05:00 AM EDT, 06/14/2024 (MT Newswires) -- Zapp Electric Vehicles Group ( ZAPP ) said it intends to appoint Bounce Electric 1 Private Limited as its contract manufacturing partner for the sales of the i300 in India. The British electric vehicle brand signed a memorandum of understanding to this effect. It said on Thursday Bounce operates a domestic vehicle assembly...

05:02 AM EDT, 06/14/2024 (MT Newswires) -- Cabaletta Bio ( CABA ) said Friday initial data from each of the first two patients dosed with its CABA-201 experimental therapy to treat autoimmune disease in early-to-mid-stage studies showed the treatment was well-tolerated and potentially effective in resetting the immune system. The company said the data showed no serious adverse events, cytokine...